ELVN20261218C50
ELVN Dec 18 2026 50.00 Call (ELVN261218C00050000)
option OPRA

enliven therapeutics focuses on the discovery and development of next generation small molecule treatments for cancer. we are backed by top-tier life science venture funds. we seek experienced and passionate drug hunters to join our team as we grow our r&d organization in boulder, co.